UGT1A1 and metabolic dysfunction-associated steatotic liver disease: We found that GNUR suppressed hepatic UGT1A1 and increased plasma bilirubin, reduced its catabolized product, urobilin [15], and lowered liver fat content and inflammation, improving NAFLD.